Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
40 Cards in this Set
- Front
- Back
- 3rd side (hint)
ANY CHEMICAL SUBSTANCE THAT HAS AN EFFECT ON LIVING TISSUE BUT IS NOT USED AS A FOOD
|
DRUG
|
ZERO TOLERANCE
|
|
RELIEVES SYMPTOMS OF DISEASE
|
THERAPEUTIC
|
|
|
PREVENT OR DECREASE SEVERITY OF DIESEASE
|
PROPHYLACTIC
|
A TOOL TO PREVENT STDS
|
|
THE SCIENCE OF DOSAGES
|
POSOLOGY
|
|
|
THE BRANCH OF PHARMACOLOGY THAT DEALS WITH THE SCIENTIFIC STUDY OF ABSORPTION, DISTRIBUTION AND EXCRETION (ADME)
|
PHARMACOKINETICS
|
|
|
THE PROCESS BY WHICH A SUBSTANCE IS TAKEN UP FROM THE SITE OF ADMINISTRATION THE SYSTEM
|
ABSORPTION
|
A=A
ADMINSTRATION= |
|
THE PROCESS OF MOVEMENT OF THE DRUG THROUGH THE BLOOD AND TRANSFER FROM THE BLOOD TO OTHER BODILY FLUIDS AND TISSUES
|
DISTRUBUTION
|
NOT A STREET PHARMACISIT, BUT A DRUG ....
|
|
THE TRANSFORMATION OF THE DRUG BY PHYSIOLOGICAL PROCESSES OF THE BODY INTO OTHER FORMS, USUALLY LESS POTENT OR TOXIC THAN THE ORIGINAL FORM THAT CAN BE ELIMINATED
|
METABOLISM
|
YOU WANT TO TRANSFORM YOUR BODY, YOU WANT TO RAISE YOUR...
|
|
THE STUDY OF DRUG ACTION ON LIVING ORGANISMS
|
PHARMACODYNAMICS
|
ACTION
|
|
THE STUDY OF OF THE ECONOMIC ASPECTS OF DRUGS
|
PHARMACOECONOMICS
|
ECONOMY
|
|
ANY CONDITION ACCOMPANYING OR RESULTING FROM A DISEASE, DISORDER OR OTHERABNORMALITY THAT PROVIDES EVIDENCE FOR ITS EXISTENCE
|
SYMPTOMS
|
GENERALLY REFERRED TO AS THE PATIENT'S DESCRIPTION OF THE PHYSICAL SENSATION EXPERIENCED
|
|
A SET OF S/SX THAT OCCUR TOGETHER AND CHARACTERIZE A PARTICULAR DISEASE OR DISORDER
|
SYNDROME
|
DISEASE=DISORDER=DOWNS
|
|
LOCATION IN THE BODY WHERE THE DRUG EXERTS ITS EFFECT. INCLUDES LOCAL USE OR SYSTEMIC USE
|
SITE OF ACTION
|
|
|
REFERS TO THE SITE SPECIFIC APPLICATION OF DRUGS, SUCH AS AN ANALGESIC OINTMENT APPLIED TO A BURN
|
LOCAL
|
YOU APPLY AN OINTMENT, IT NUMBS CREATING A ... ANALGESIC
|
|
REFERS TO APPLICATION OF A DRUGBY MEANS OF ABSORPTION INTO THE BLOOD AND SUBSEQUENT TRANSPORTATION THROUGHOUT THE BODY
|
SYSTEMIC
|
ABSORBS INTO BLOOD
|
|
HOW THE DRUG PRODUCES ITS EFFECTS IN THE BODY. INCLUDES AGONIST/ANTAGONIST EFFECT/NONSPECIFIC MEMBRANE LIPID INTERACTION/PROTEIN BINDING/OSMOTIC EFFECT
|
MECHANISM OF ACTION
|
|
|
LOCATION ON THE SURFACE OR WITHIN THE CELL THAT CONTAIN SPECIFIC PROTEIN MOLECULES THAT BIND TO OTHER SPECIFIC MOLECULES, PRODUCING SOME EFFECT IN THE CELL.
|
RECEPTOR SITE
|
LOCATION
|
|
A DRUG THAT BINDS TO PARTICULAR RECEPTOR SITE AND TRIGGERS THE CELLS RESPONSE IN A SIMILAR WAY TO THE BODY'S OWN CHEMICAL MESSENGER
|
AGONIST
|
RESPONSE IN A SIMILAR WAY
|
|
A DRUG THAT BINDS TO A PARTICULAR RECEPTOR SITE AND BLOCKS THE ACTION OF THE ENDOGENOUS CHEMICAL MESSENGER WITHOUT TRIGGERING THE CELL'S RESPONSE.
|
ANTAGONIST
|
BLOCKS THE ACTION
|
|
THE MAXIMUM THERAPEUTIC DOSE, ABOVE WHICH NO IMPROVED CLINICAL RESPONSE WILL OCCUR
|
CEILING EFFECT
|
|
|
THE LENGTH OF TIME A DRUG IS AT THERAPEUTIC CONCENTRATION LEVEL
|
DURATION OF ACTION (DOA)
|
|
|
THE TIME PERIOD REQUIRED AFTER ADMINISTRATION OF A DRUG TO ACHIEVE THE DESIRED RESPONSE, OR THERAPEUTIC CONCENTRATION LEVEL.
|
ONSET OF ACTION
|
TIME PERIOD
|
|
THE DRUG DOSE THAT WILL PRODUCE A THERAPEUTIC RESPONSE IN 50 PERCENT OF THE POPULATION WHO RECEIVED THE DRUG
|
EFFECTIVE DOSE 50
|
|
|
THE DOSAGE THAT WILL KILL 50% OF THE POPULATION
|
LETHAL DOSE 50
|
|
|
UNUSUAL OR UNEXPECTED RESPONSE TO A DRUG. PECULIAR TO THE INDIVIDUAL AND SOMETIMES HAVE GENETIC CAUSES
|
IDIOSYNCRASY
|
|
|
A LOCAL OR GENERAL IMMUNE RESPONSE IN WHICH THE IMMUNE SYSTEM OVERREACTS TO AN OTHERWISE HARMLESS SUBSTANCE
|
ALLERGY
|
|
|
RESULTING IN IMMEDIATE LIFE THREATENING RESP DISTRESS, USUALLY FOLLOWED BY VASCULAR COLLAPSE AND SHOCK AND ACCOMPANIED BY HIVES
|
SEVERE ALLERGIC REACTION
|
|
|
LONGEST DIFFICULT NAME OF THE CHEMICAL MAKE UP THE DRUG AND RELATES TO THE CHEMICAL AND MOLECULAR STRUCTURE
|
CHEMICAL NAME
|
|
|
A SHORTENED VERSION OF THE CHEMICAL NAME THAT THE MANUFACTURER GIVES THE DRUG
|
GENERIC NAME
|
BEGINS WITH LOWERCASE LETTER AND CAN BE USED BY OTHER MANUFACTURERS
|
|
THE NAME UNDER WHICH THE MANUFACTURER HAS PATENTED THE DRUG
|
TRADE/BRAND NAME
|
|
|
THE BRANCH OF PHARMACOLOGY THAT DEALS WITH BIOLOGICAL, BIOCHEMICAL, AND ECONOMIC FEATURES OF NATURAL DRUGS AND THEIR CONSTITUENTS
|
PHARMACOGNOSY
|
|
|
PROVIDES STANDARDS FOR DRUGS OF THERAPEUTIC USEFULNESS AND PHARMACEUTICAL NECESSITY.
|
US PHARMACOPEIA AND NATIONAL FORMULARY
|
|
|
THE MOST WIDELY USED TEXT/REFERENCE IN AMERICAN PHARMACIES
|
REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY
|
|
|
THE THERAPEUTIC DOES IS CALCULATED ON AN AVERAGE ADULT
|
24 YEARS WHO WEIGHS 150 POUNDS
|
|
|
DRUGS GROUPED ACCORDING TO THEIR SOURCE, WHETHER ANIMAL, VEGETABLE, OR MINERAL IN ORIGIN
|
GENERAL
|
|
|
DRUGS GROUPED BY THEIR CHEMICAL CHARACTERISTICS
|
CHEMICAL
|
|
|
DRUGS ARE GROUPED ACCORDING TO THEIR ACTION ON THE BODY
|
THERAPEUTIC
|
|
|
HISTAMINE H2 RECEPTOR ANTAGONISTS
|
BLOCKS HISTAMINES THAT CAUSE AN INCREASE OF OF GASTRIC ACID SECRETION IN THE STOMACH. RELIEVES SYMPTOMS OF PEPTIC ULCERS
|
|
|
EFFECTIVE AGAINST BOTH GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS. WERE THE FIRST EFFECTIVE CHEMOTHERAPEUTIC AGENTS AVAILABLE
|
SULFONAMIDES
|
|
|
MOST EFFECTIVE AND LEAST TOXIC OF THE ANTIMICROBIAL AGENTS
|
PCN
|
|